Search

Purpose: To determine the efficacy of the combined use of carboprost tromethamine and ergometrine in the prevention and treatment of postpartum hemorrhage induced by uterine atony.Methods: A total of 66 pregnant women with postpartum hemorrhage due to uterine atony who were treated in Fuyang Women's and Children's Hospital from February 2019 to January 2022 were randomly and equally assigned to control and combination groups, respectively, based on the order of admission. The control group was treated with 0.2 mg of ergometrine maleate via intramuscular injection in the buttocks. In the combination group, the patients were also given 250 μg of carboprost tromethamine via cervical injection in addition to ergometrine. The two groups were compared in terms of volume of postpartum vaginal bleeding and hemoglobin levels, coagulation function index, clinical effectiveness and incidence of adverse reactions.Results: There was a significant difference in total treatment effectiveness between the two groups (69.70 vs 90.91%; ꭓ2 = 4.694, p = 0.03) with the combination group showing higher effectiveness. The volume of bleeding in the combination group at 2 h and 24 h after delivery were significantly lower than the corresponding values for the control group (p < 0.05). Comparison at 24 h postpartum showed significantly lower hemoglobin level in the combination group than in the control group (p < 0.05). Posttreatment levels of prothrombin time (PT) and thrombin time (TT) in the two groups were lower than the pre-treatment values, but the post-treatment levels in the combination group were lower than those in the control group (p < 0.05).Conclusion: Combined administration of carboprost tromethamine and ergometrine may be a viable treatment strategy for uterine atony-induced postpartum hemorrhage. It has acceptable level of safety. However, further clinical trials are required prior to application in clinical practice.

Ning Sun,1,2 Chunxia Yang,1 Xiaoting He,1,3 Zhifen Liu,1 Sha Liu,1 Xinrong Li,1 Yanfang Wang,1 Ruihua Jin,2 Kerang Zhang1 1Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China; 2Nursing College of Shanxi Medical University, Taiyuan, People’s Republic of China; 3University-Town Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Ruihua Jin; Kerang Zhang Email jrh_xy@163.com; atomsxmu@vip.163.comBackground: Patients suffering from major depressive disorder (MDD) commonly demonstrate lower performance across multiple cognitive domains. Cognitive impairment is an intrinsic characteristic of MDD status and is often influenced by genetic factors. microRNAs (miRNAs or miRs) have been shown to have important implications in the etiology of MDD. Therefore, we aimed to identify and analyze the impact of expression and genetic variation of miR-34b/c on cognitive dysfunction in MDD.Methods: First, we analyzed miR-34c-5p expression in 48 cases of MDD and 54 healthy controls in a Chinese population using qRT-PCR. We assessed the relationship between the level of miR-34c-5p expression and cognitive performance by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Trail Making Test (TMT). Second, in order to characterize allelic effects of miR-34b/c on cognitive performance in MDD patients, we performed genetic association analysis of single-nucleotide polymorphism (SNP) loci of the MIR34B/C genes with cognitive function in a second group consisting of 531 MDD patients and 267 healthy controls.Results: We found a significant negative correlation between the level of miR-34c-5p expression and both the language and delayed memory index scores in patients with MDD. We also found a significant positive correlation between the level of miR-34c-5p expression and the time required to complete tests A and B of the TMT. The interaction between the rs2187473 genotype and the disease was significant for both immediate memory and delayed memory. In the patient group, the rs2187473 CC genotype was significantly associated with higher performance on immediate memory (F = 6.683, p < 0.05) and delayed memory tasks (F = 4.221, p < 0.05).Conclusion: Our findings suggest that changes in miR-34c expression level have important impacts on cognitive function in patients with MDD. In particular, the polymorphism rs2187473 is a potential genetic risk factor for cognitive function in MDD, which may be of clinical use.Keywords: major depressive disorder, MDD, microRNA-34c, single-nucleotide polymorphism, cognitive function